BNTX

MKT CAP:$26B

BioNTech SE

Market Cap

$26B

Healthcare·Biotechnology·🇩🇪 Germany·NASDAQ

Healthcare·Biotechnology·🇩🇪·NASDAQ

Stock Price

$105.42+$8.73 (+9.03%)

Apr 24, 2026

Company Details

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advan...

CEO

Ugur Sahin

IPO Date

Oct 10, 2019

Website

www.biontech.de

Key Metrics TTM

Revenue

$1.1B

— YoY

Net Income

-$509M

EPS (Diluted)

-$2.13

Free Cash Flow

$50M

Revenue / Share

$4.68

Gross Margin

64.8%

Operating Margin

-38.2%

Net Margin

-44.4%

FCF Margin

4.4%

P/S

23.1x

P/E

—

Earnings Reports

Q1 2026

May 4, 2026

PENDING

FY 2025

Mar 10, 2026

$3.2BEPS -$5.27

Q4 2025

Mar 10, 2026

$1.1BEPS -$1.44

Q1 2020

Mar 31, 2020

$32M+5.9%EPS -$0.28

FY 2019

Dec 30, 2019

$127MEPS -$0.99

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 18	$25M	$22M	-$17M
Q2 18	$25M	$22M	-$17M
Q1 19	$31M	$27M	-$51M
Q2 19	$30M	$24M	-$56M
Q3 19	$34M	$29M	-$43M
Q1 20	$32M	$25M	-$69M
Q4 25	$1.1B	$665M	-$270M

Valuation

Quarter	P/S	P/E
Q1 18	—	—
Q2 18	—	—
Q1 19	—	—
Q2 19	26.2x	—
Q3 19	24.4x	—
Q1 20	108.9x	—
Q4 25	19.9x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 18	-$41M	-$48M
Q2 18	-$41M	-$48M
Q1 19	-$36M	-$76M
Q2 19	-$64M	-$71M
Q3 19	-$58M	-$82M
Q1 20	-$64M	-$74M
Q4 25	$350M	$278M

Capital Expenditures

Quarter	CapEx
Q1 18	$7M
Q2 18	$7M
Q1 19	$39M
Q2 19	$8M
Q3 19	$25M
Q1 20	$10M
Q4 25	$72M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 19	+32.1%	+79.0%
Q1 20	+27.7%	+137.6%
Q4 25	+3336.9%	+1513.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 18	$0	0.0%
Q2 18	$0	0.0%
Q1 19	$16M	51.6%
Q2 19	$5M	17.4%
Q3 19	$5M	15.7%
Q1 20	$10M	30.3%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 18	$34M	$6M	$710.3K
Q2 18	$34M	$6M	$710.3K
Q1 19	$67M	$10M	$654.7K
Q2 19	$62M	$15M	$792.7K
Q3 19	$59M	$12M	$783.4K
Q1 20	$76M	$18M	$584.6K
Q4 25	$585M	$283M	$58M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$7.2B	$1M	$7.2B
Q2 22	$10.9B	$116.9K	$10.9B
Q3 22	$15.7B	$6M	$15.7B
Q4 22	$16.2B	$221M	$16.4B
Q1 23	$15.4B	$0	$15.4B
Q2 23	$16.6B	$1.6B	$18.2B
Q3 23	$15.8B	$2.6B	$18.4B
Q4 23	$13.6B	$5.7B	$19.3B
Q1 24	$10.5B	$7.8B	$18.3B
Q2 24	$12.1B	$8.1B	$20.2B
Q3 24	$11.3B	$8.3B	$19.5B
Q4 24	$11.4B	$8.2B	$19.6B
Q1 25	$11.9B	$4.6B	$16.5B
Q2 25	$12.0B	$4.4B	$16.4B
Q3 25	$11.8B	$5.2B	$17.0B
Q4 25	$9.0B	$8.4B	$17.3B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 18	194M	—	—
Q2 18	194M	0.0%	—
Q1 19	227M	+17.2%	—
Q2 19	229M	+1.1%	—
Q3 19	229M	0.0%	+18.5%
Q1 20	223M	-3.0%	+14.9%
Q4 25	245M	+10.2%	+8.1%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 18	—	—
Q2 18	—	—
Q1 19	—	—
Q2 19	—	—
Q3 19	—	—
Q1 20	$24.7K	1K
Q4 25	$134.6K	8K

Revenue / Employee